These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival. Fisher ML, Keillor JW, Xu W, Eckert RL, Kerr C. Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691 [Abstract] [Full Text] [Related]
7. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Agnihotri N, Kumar S, Mehta K. Breast Cancer Res; 2013 Feb 25; 15(1):202. PubMed ID: 23673317 [Abstract] [Full Text] [Related]
9. Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical pathway. Kumar S, Mehta K. PLoS One; 2012 Feb 25; 7(11):e49321. PubMed ID: 23185316 [Abstract] [Full Text] [Related]
10. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR, Massoll NA, Brown KD. Carcinogenesis; 2008 Mar 25; 29(3):510-8. PubMed ID: 18174247 [Abstract] [Full Text] [Related]
13. Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues. Park KS, Kim DS, Jeong KC, Kim SY. Front Biosci (Landmark Ed); 2009 Jan 01; 14(5):1945-51. PubMed ID: 19273176 [Abstract] [Full Text] [Related]
14. Transglutaminase 2 and NF-kappaB interplay during NGF-induced differentiation of neuroblastoma cells. Condello S, Caccamo D, Currò M, Ferlazzo N, Parisi G, Ientile R. Brain Res; 2008 May 01; 1207():1-8. PubMed ID: 18374307 [Abstract] [Full Text] [Related]
15. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB, Mehta K. Breast Cancer Res; 2012 Jan 06; 14(1):R4. PubMed ID: 22225906 [Abstract] [Full Text] [Related]
16. Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor. Han AL, Kumar S, Fok JY, Tyagi AK, Mehta K. Eur J Cancer; 2014 Jun 06; 50(9):1685-96. PubMed ID: 24656569 [Abstract] [Full Text] [Related]
17. Transglutaminase 2 modulation of NF-κB signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury. Feola J, Barton A, Akbar A, Keillor J, Johnson GVW. Brain Res; 2017 Aug 01; 1668():1-11. PubMed ID: 28522262 [Abstract] [Full Text] [Related]
18. IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. Oh K, Lee OY, Park Y, Seo MW, Lee DS. BMC Cancer; 2016 Sep 08; 16(1):724. PubMed ID: 27609180 [Abstract] [Full Text] [Related]
19. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Blood; 2012 Mar 15; 119(11):2568-78. PubMed ID: 22294726 [Abstract] [Full Text] [Related]